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of the intervention under evaluation were found both in the percentage of patients
maintaining total abstinence as well as in the percentage of relapsed patients.
Statistically significant in favor of naltrexone treatment when assessing too such
endpoint as alcohol craving intensity assessment for the NAL/PSY vs ACA/PSY
analysis in a long treatment period and for the NAL/PSY vs PL/PSY analysis in a
short term.Long-term results (52 weeks) of the analysis quoted indicate on a com-
parable clinical efficacy (no statistical significance of results obtained) of the use of
naltrexone and placebo in the group of alcohol-dependent patients undergoing
psychotherapy.The adverse events related to naltrexone treatment are usually
mild and transient. The most frequent ones are: headaches, sleep disorders, anx-
iety, nervousness, gastrointestinal disorders such as abdominal pain, nausea,
vomiting. CONCLUSIONS: Summing up, the results of the analysis carried univo-
cally prove that naltrexone administered in a 50mg dose a day is an effective and
safe drug in the treatment of alcohol dependent patients who additionally undergo
a psychotherapy.
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IMPACT OF ADHERENCE TO FIRST THERAPY ON THE RISK OF
ANTIDEPRESSANT SWITCHING
Jung SY, Shin S, Song H, Park J, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: To assess the impact of adherence to first antidepressant (AD) ther-
apy on risk of AD switching, using nationwide claims database. METHODS: Using
the Korean Health Insurance Review & Assessment Service (HIRA) claims database
(2006-2008), newly diagnosed depression patientswho aged 18-84,withoutmedical
visit due to depression (ICD 10F06.3, F31.3, F31.4, F32, F33, F34.1, F38.1, F41.2)
within 6 months before the first observed prescription of ADs between Jul 2006 to
Jun 2007 (18 months index period), and with at least 3 psychiatric visits within 3
months from index date were identified. ADs were categorized as tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and new antide-
pressants (NADs). For each AD category, adherence by 90 days post-index period
Medication possession ratio (MPR) was estimated. Switching was defined prescrip-
tion of different class of AD therapy from last AD regimen. Time to first switching
was assessed. Cox proportional hazards model was used to investigate the rela-
tionship between adherence to AD and time to switch. RESULTS: A total of 88,079
patients satisfied the selection criteria, among which mean age of 45.2 years and
67.3% of women.When assessed AD therapywithin 90 days from index date, 31.3%
of the patients prescribed SSRI monotherapy, 16.4% prescribed TCAmonotherapy,
and 15.2% prescribed SSRINAD polytherapy. Overall rate of switching was 38.1%.
When adjusted for age, gender, and AD regimen, patients with higher adherence
(MPR75%) showed lower rate of switching (adjusted OR0.93[95% CI0.91-0.95]).
CONCLUSIONS: Switching AD therapy can be inferred as indicator of insufficient
effectiveness or adverse drug reaction. Improving adherence to AD therapy in
newly diagnosed depression patients is important to prevent the switching AD
therapy afterwards.
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CHARACTERISTICS OF PATIENTS IN COMMUNITY BEHAVIORAL HEALTH
ORGANIZATIONS RECEIVING TWO INJECTABLE FORMS OF ATYPICAL
ANTIPSYCHOTIC MEDICATIONS AS COMPARED WITH OTHER
ANTIPSYCHOTICS
Mark T1, Panish J2, Mao L2, Montejano LB3, Dirani R4, Fastenau J2, Starr HL2
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OBJECTIVES: To describe characteristics of patients with schizophrenia receiving
treatment with atypical injectable antipsychotics paliperidone palmitate and ris-
peridone long-acting as compared to other antipsychotics therapy at community
behavioral health organizations (CBHOs) in the United States.METHODS: A longi-
tudinal, noninterventional observational registry, Research and Evaluation of An-
tipsychotic Treatment in Community Behavioral Health Organizations OUTcomes
(REACH OUT) is collecting information on use of paliperidone palmitate, risperi-
done long-acting therapy (LAT), and other antipsychotics by patients with schizo-
phrenia or bipolar type I disorder receiving treatment at CBHOs. Patients are fol-
lowed for 1 year, with assessments at baseline, 6, and 12 months. Sites use a
Web-based data-collection tool to enter patient self-reports, interviewer assess-
ments, and medical record abstractions. RESULTS: At time of analysis, baseline
patient interview data from 114 patients with schizophrenia were collected at 10
sites in the following cohorts: 44% paliperidone palmitate injections, 33% risperi-
done injections, and 23% other antipsychotics. Patients in the paliperidone palmi-
tate or risperidone LAT cohorts were older, on average, than those receiving other
antipsychotics: paliperidone palmitate, 41.2 years; risperidone LAT, 43.0; other an-
tipsychotics, 35.0. Mean age at first psychiatric hospitalization was older for pali-
peridone palmitate (23.1) and risperidone LAT (24.4) than for other antipsychotics
(20.1). Patients receiving the two injectable antipsychotics were more likely to be
male (paliperidone palmitate, 70.0%; risperidone LAT, 73.7%; other antipsychotics,
69.2%) and single/never married (paliperidone palmitate, 78.0%; risperidone LAT,
78.9%; other antipsychotics, 69.2%). Patients treated with atypical antipsychotic
injectionswere less likely to have private health insurance (paliperidone palmitate,
6.0%; risperidone LAT, 0.0%; other antipsychotics, 19.2%) and more likely to have
Medicare (paliperidone palmitate, 60.0%; risperidone LAT, 60.5%; other antipsy-
chotics, 23.1%) or Medicaid (paliperidone palmitate, 82.0%; risperidone LAT, 78.9%;
other antipsychotics, 46.2%). CONCLUSIONS: Results suggest that patients in CB-
HOs receiving paliperidone palmitate and risperidone injections may differ from
patients receiving other antipsychotics io sociodemographics.
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PREVALENCE OF ANTICHOLINERGIC DRUG PRESCRIBING IN ELDERLY
OUTPATIENTS WITH DEMENTIA
Bhattacharya R, Chatterjee S, Aparasu R
University of Houston, Houston, TX, USA
OBJECTIVES: Anticholinergic medications, though frequently used in the elderly
population, are associated with cognitive impairment and use of these agents is a
concern in dementia patients. This study examined the prevalence and predictors
of anticholinergic prescribing in elderly outpatients with dementia. METHODS:
Data from 2006–2007 National Ambulatory Medical Care Survey (NAMCS) and the
outpatient National Hospital Ambulatory Medical Care Survey (NHAMCS) were
combined to analyze elderly (65 years or older) patient visits for dementia (ICD-
9-CM codes-290.XX, 291.2, 294.XX, 331.XX, 046.1 and 046.3). Anticholinergic drugs
were identified using a preexisting scale, the Anticholinergic Drug Scale (ADS),
which classified anticholinergic drugs into four levels in increasing order of their
anticholinergic activity. Descriptive analysis was used to evaluate prevalence pat-
terns and multiple logistic regression was conducted to examine the factors asso-
ciated with prescribing of medications with marked anticholinergic activity (Level
2 or Level 3). RESULTS: According to the 2006-2007 NAMCS and NHAMCS data,
there were a total of 6.8 million (95% Confidence Interval (CI) 5.27-8.44 million,
0.32%) ambulatory care visits for dementia. Nearly 43% (95% CI 35.24%-50.48%) of
all elderly dementia patient visits involved prescribing of at least one anticholin-
ergic drug; 36.76% of the above visits involved Level 1 medications, 10.85% of visits
involved Level 2 or Level 3 medications. While age (75-84 years; Odds Ratio (OR)
0.26, 95% CI0.08-0.85) and acetylcholine esterase inhibitor use (OR 0.21, 95% CI
0.07-0.65) increased the likelihood of prescribing medications with marked anti-
cholinergic activity, total number of medications prescribed also (OR 1.41, 95% CI:
1.81-1.67) increased the likelihood of these prescriptions.CONCLUSIONS:Over 10%
of elderly dementia visits involved prescribing of medications with marked anti-
cholinergic activity. Given the severe cognitive adverse events, there is strong need
to optimize anticholinergic drug prescribing in elderly outpatients with dementia.
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IMPACT OF COGNITIVE IMPAIRMENT ON FUNCTIONING, MEDICAL RESOURCE
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OBJECTIVES: To examine the influence of cognitive impairment on functioning,
medical resource utilization, adherence, and health-related quality of life (HRQoL)
in patients with schizophrenia. METHODS: Data analyzed were from a cross-sec-
tional study of patients with schizophrenia and their physicians (2005 Adelphi US
Psychoses XI Disease Specific Programme). Outpatient schizophrenia patients aged
18 years with 4 physician encounters in the past 12 months were identified.
Physicians evaluated their patients’ cognitive impairment, positive and negative
symptoms, functioning (employment status, presence of a caregiver, global assess-
ment of functioning (GAF) scale, Likert scales measuring overall function and abil-
ity to meet own basic needs), adherence, and resource utilization. HRQoL (EQ-5D
tariff and visual analog scale (VAS), Likert scales measuring overall sense of well
being, overall life satisfaction, and satisfaction with relationships) and adherence
data were collected directly from patients. Multivariate analyses were used to ex-
amine the predictors for each outcome variable. Covariates included patients’ de-
mographics and their comorbidities. RESULTS: Eighty one percent of the 839
schizophrenia patients had cognitive impairment. A higher level of cognitive func-
tion was associated with higher overall functioning and GAF scores, improved
ability tomeet basic needs, being employed, not having a caregiver, fewer ER visits,
greatermedication adherence, better HRQoL (EQ-5D and VAS scores), overall sense
of well-being, and higher satisfaction with life and social relationships (p0.05).
The severity of positive and negative symptoms was positively associated with
poorer functioning, number of outpatient visits, and poorer HRQoL. Severe positive
symptoms also predicted more hospitalizations and poorer adherence (p0.05).
Cognitive impairment was associated with fourteen outcomes, while positive and
negative symptoms predicted nine and six outcomes respectively. CONCLUSIONS:
Cognitive impairment in schizophrenia patients is significantly associated with
a number of measures of disease burden, which can substantially increase the
impact of the disease beyond that associated with only positive and negative
symptoms.
Mental Health – Cost Studies
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THE BUDGET IMPACT ANALYSIS OF NALTREXONE IN THE TREATMENT OF
ALCOHOL-DEPENDENT PATIENTS IN POLAND
Walczak J, Semeniuk A, Pacocha K, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: The purpose was to estimate financial consequences of naltrexone
reimbursement in the treatment of alcohol-dependent patients in Poland.
METHODS: The budget impact analysis was conducted for two-years time horizon
from the public payer perspective (National Health Fund) and, additionally, form
the patient perspective. The target population consisting of the alcohol-dependent
patients, who are treated in dependent treatment centres and are eligible for nal-
trexone therapy was estimated on the basis of epidemiological data and clinical
expert’s opinion. In the analysis two scenarios were compared: present, in which
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none of the drugs supporting psychotherapy in treatment of alcoholism is reim-
bursed, and new, in which naltrexone is reimbursed within the catalogue of guar-
anteed health services in the treatment of alcohol-dependent patients. The anal-
ysis presents the costs incurred by public payer and by patient associated onlywith
drugs that support psychotherapy in the considered target population. The costs
were not discounted. Consumption of resources was estimated on the basis of
epidemiological data and recommended duration of pharmacotherapies. The ef-
fect of changes of key parameters and assumptions of primary analysis on the
results obtained from the perspective of the public payer was examined in the
one-way sensitivity analysis. RESULTS: If the reimbursement of naltrexone is in-
troduced, the annual expenses from the budget of National Health Fund would
increase by PLN11.7million in the first year, and PLN11.8million in the second year
of reimbursement. On the other hand, from the patient perspective reimbursement
of naltrexonewill bring significant cost savings whichwill annually amount to PLN
28.8 million in the first and second year of the refund. CONCLUSIONS: Reimburse-
ment of naltrexone in the treatment of alcohol-dependent patients in Poland will
bring additional costs incurred by public payer (National Health Fund) andpatient’s
significant cost savings.
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PSYCHOTROPIC MEDICATION USE AMONG CHILDREN WITH AUTISM
SPECTRUM DISORDER: A COMPARISON BETWEEN MEDICAID AND
COMMERCIAL INSURANCE
Wang L, Leslie D
Penn State College of Medicine, Hershey, PA, USA
OBJECTIVES:To comparepatterns of psychotropicmedicationuse and the associated
costs among children with autism spectrum disorder (ASD) between public and pri-
vate insurance to bridge a knowledge gap in the literature.METHODS: Retrospective
analyses were done using year 2003 claims data from Medicaid and the MarketScan
databases, a national sample of privately insured individuals. Two-sample z-tests
were used to compare the proportions. T-testswere used to compare themeans given
the large sample size. RESULTS:A total of 18,166 childrenwith ASDwere identified in
Medicaid and 2,716 in MarketScan. Psychotropic medication was used by 86% of ASD
children in Medicaid and 78% in MarketScan. The psychotropic medication costs per
ASD patient were nearly twice higher in Medicaid ($1464 vs. $796, p0.0001). The
twelve most costly psychotropic drugs accounted for 82% of all psychotropic drug
costs, with Medicaid spending more on all these drugs. Risperidone, the most costly
drug in both systems, cost $391 per ASD patient in Medicaid and $218 in MarketScan.
ThehigherMedicaid costwas due tomore users (27%vs. 18%) andhigher average cost
per risperidone user ($1612 vs. $1242). Though the unit cost was similar, the average
lengthof therapywas longer inMedicaid (241vs. 210days). Similarpatternsexisted for
other drugs such as olanzapine, the second most costly psychotropic medication in
Medicaid. Medicaid hadmore olanzapine users (7.4% vs. 4.5%), higher costs per olan-
zapineuser ($2276vs. $1302)due tomoredays supplied (211vs. 156days),with theunit
cost being similar. CONCLUSIONS: Children with ASD in Medicaid had much higher
psychotropicdrug costs than those in commercial insurance. Similar drugswereused,
but the same drugs cost much more in Medicaid, due to a higher percentage of chil-
dren on the medication and a greater duration of use.
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DIFFERENCES IN DAILY AVERAGE CONSUMPTION AND DAILY COSTS OF
DESVENLAFAXINE, VENLAFAXINE XR, DULOXETINE, AND ESCITALOPRAM
AMONG COMMERCIALLY INSURED PATIENTS
Whiteley J1, Makin C2, Klingman D2, Alvir J1, Harnett J1
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BACKGROUND: Differences in daily utilization of antidepressant therapies may
have clinical and economic implications, particularly pharmacy expenditures for
health plans. OBJECTIVES: To examine antidepressant daily average consumption
(DACON) and drug cost per day for patients with major depressive disorder (MDD)
newly initiating serotonin- norepinephrine reuptake inhibitors (SNRIs) or
escitalopram. METHODS: A retrospective cohort analysis was conducted in com-
mercially insured patients from July 1, 2008 through June 30, 2009. Patients diag-
nosed with MDD (ICD-9: 296.2x, 296.3x, or 311) and newly treated with generic
desvenlafaxine, venlafaxine XR, duloxetine, or escitalopram were included. For
each index medication, DACON was computed for each pill strength by dividing
total units dispensed by total days’ supply while the patient persisted on index
therapy, then averaging across pill strengths,weighted by days’ supply. Persistence
was defined as length of therapy without exceeding a 30-day gap in drug coverage,
and drug cost per daywas estimated based on standardwholesale acquisition cost.
RESULTS: The study population included 1,097 desvenlafaxine, 1,924 venlafaxine
XR, 3,216 duloxetine, and 4,730 escitalopram initiators. Average DACON during the
study period was significantly lower (P0.001) for desvenlafaxine (1.04) vs venla-
faxine XR (1.43), duloxetine (1.28), or escitalopram (1.07). Average cost per DACON
during the study periodwas significantly lower (P0.001) for desvenlafaxine ($3.89)
vs venlafaxine XR ($6.13) and duloxetine ($5.45), but higher than escitalopram
($3.21). Average persistence (days) was significantly greater for desvenlafaxine
(140.6) vs venlafaxine XR (127.3; P0.001), duloxetine (133.4; P0.007), and escita-
lopram (121.8; P0.001). CONCLUSIONS: Patients with MDD treated with desven-
lafaxine had significantly lower DACON and greater persistence on index antide-
pressant therapy than patients treated with venlafaxine XR, duloxetine, or
escitalopram, and the lowest DACON cost among the SNRIs. Health care decision
makersmaywish to consider utilization patterns and their economic impact when
determining health care policy and treatment decisions.
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CLINICAL AND ECONOMIC CONSEQUENCES OF LONG-TERM USE OF
BENZODIAZEPINES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
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OBJECTIVES: To compare patterns of healthcare utilization and cost in the
6-month periods immediately before and after the initiation of benzodiazepine
therapy among patients with generalized anxiety disorder (GAD) deemed long-
termusers of such therapy.METHODS:Using a largeUShealth insurance database,
we identified all persons with evidence of GAD (ICD-9-CM diagnosis code 300.02)
between 1/1/2003 and 12/31/2007 who began treatment with a benzodiazepine
anxiolytic. The date of the first benzodiazepine claim was designated the “index
date”, andwe limited attention to patientswith evidence of use of benzodiazepines
for 90 days. Patients with 6 months of complete data preceding and following
their index date were excluded from the study sample (“pre-index” and “post-
index”, respectively). We then compared healthcare utilization and costs between
the 6-month pre-index and post-index periods. All healthcare utilization—and cor-
responding costs—was characterized as possibly attributable to long-term use of
benzodiazepines (such as “accident-related” [e.g., fractures] or “other possibly re-
lated” [e.g., mental confusion/disorientation, cognitive impairment, dizziness]) or
not, based on relevant ICD-9-CM diagnosis codes. RESULTS:We identified a total of
866 patients who initiated benzodiazepine therapy for GAD and who met all other
entry criteria; 75% began monotherapy with benzodiazepines, and 25% received
such therapy on an add-on basis. Mean total healthcare costs over the 6-month
post-index period increased by $2334 relative to pre-index (from $4637 [SD$9840]
to $6971 [$17,002]; p0.01); the corresponding increase for care possibly attributed
to long-term use of benzodiazepines (i.e., accident-related, other possibly related)
was $1099 ($1757 [$7656] vs. $2856 [$14,836]; p0.04). CONCLUSIONS: Healthcare
costs increase in patients with GAD who receive90 days of benzodiazepine ther-
apy; a substantial proportion of this increase is attributable to care associated with
accidents and other known sequelae of long-term benzodiazepine use.
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COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN
PATIENTS WHO WERE TREATED WITH AND WITHOUT MEDICATION FOR
OPIOID DEPENDENCY
Baser O, Wang L, Xie L
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To compare the differences in healthcare costs and utilizations be-
tween opioid-dependent patients who were treated with and without medication.
METHODS:We conducted a retrospective database analysis using commercial en-
rollees from a large U.S. health plan database from 2005 to 2009. Continuously
eligible patients with at least one claim of opioid dependence during the identifi-
cation period and an opioid use disorder diagnosis during the baseline period were
included. Propensity score matching was applied to compare the risk-adjusted
outcomes between the Any Medication Group and the No Medication Group. Base-
line differences in age, gender, region, comorbid scores, socio-economic status,
baseline healthcare utilization and costs were controlled. RESULTS: Descriptive
analysis showed that patients in the AnyMedication Group (n10,523) were sicker,
had more distinct psychiatric diagnoses and medication, and were more likely to
have an Elixhauser index score ofmore than 3when compared to patients from the
No Medication Group (n8,630). After risk adjustments, 6,658 patients from each
group were matched. Patients in the No Medication Group stayed significantly
longer in detoxification facilities, and had a higher number of detoxification and/or
rehabilitation admissionwhich translated to a higher cost burden. Also, patients in
the No Medication Group had more opioid-related and substance abuse psychos-
ocial provider services and higher total healthcare costs during a 6-month post-
index period compared to patients in the Any Medication Group. CONCLUSIONS:
After controlling for confounders such as demographic factors, comorbid condi-
tions and baseline healthcare utilization, we showed that medication treatment
affects follow-up healthcare resource utilization and costs. Patients treated with-
outmedication incurredhigher healthcare costs andutilizations thanpatientswho
were treated with medication.
PMH24
COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN
PATIENTS WHO WERE TREATED WITH PHARMACOLOGICAL AND NON-
PHARMACOLOGICAL SUBSTANCE MEDICATIONS FOR ALCOHOL DEPENDENCY
Baser O, Wang L, Xie L
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To compare the differences in healthcare costs and utilizations be-
tween alcohol-dependent patients treated with pharmacological substances and
those treated with non-pharmacological substance medication. METHODS: We
conducted a retrospective database analysis using commercial enrollees from a
large U.S. health plan database from 2005 to 2009. Continuously eligible patients
with at least one claim of alcohol dependence during the identification period and
an alcohol use disorder diagnosis during the baseline period were included. Pro-
pensity score matching was applied to compare the risk-adjusted outcomes be-
tween the No-Pharmacological Substance Group and the Any Pharmacological
Substance Group. Baseline differences in age, gender, region, comorbid scores,
socio-economic status, and baseline healthcare utilization and costs were
controlled. RESULTS: Descriptive analysis shows that patients in the Any Pharma-
cological Substance Group (n15,502) were older, more likely to be female, had
more distinct psychiatric diagnoses and medication, and were more likely to have
an Elixhauser index score of more than 3 when compared to patients from the
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